BREAKING NEWS

BioNTech to price coronavirus vaccine below market rates

By REUTERS

NOVEMBER 10, 2020 12:26

BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.

Speaking at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would reflect the financial risks that its private-sector investors have incurred.

"We’ve tried to pursue a balanced approach that recognizes that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we're in and with the goal to insure broad-based access around the world," Richardson said at the FT event.

"I expect there to be differential pricing in certain regions of the world," he added, declining to elaborate on the different price tags.

Trump: Kamala will start WW3, get millions of Muslims killed

By JERUSALEM POST STAFF

11/05/2024 01:10 PM

Putin tells Western diplomats Russia is committed to cooperation

By REUTERS

11/05/2024 01:08 PM

Iranian-German Sharmahd died before his execution, Iran judiciary says

By REUTERS

11/05/2024 12:33 PM

Iranian female student who stripped in public is 'troubled'

By REUTERS